In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

The diagnostic role of cardiac magnetic resonance imaging when performed as initial test in suspected non-ST elevation myocardial infarction

Session Rapid Fire Abstract 3: stress CMR: utility in coronary artery disease and beyond

Speaker Yvonne Van Cauteren

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Stress CMR
  • Session type : Rapid Fire Abstracts
  • FP Number : 306

Authors : YJM Van Cauteren (Maastricht,NL), MW Smulders (Maastricht,NL), J Heijman (Maastricht,NL), SC Gerretsen (Maastricht,NL), RALJ Theunissen (Maastricht,NL), AMA Mingels (Maastricht,NL), SMJ Van Kuijk (Maastricht,NL), RJ Kim (Durham,US), HJGM Crijns (Maastricht,NL), JE Wildberger (Maastricht,NL), SCAM Bekkers (Maastricht,NL)

Authors:
YJM Van Cauteren1 , MW Smulders1 , J Heijman1 , SC Gerretsen1 , RALJ Theunissen1 , AMA Mingels1 , SMJ Van Kuijk2 , RJ Kim3 , HJGM Crijns1 , JE Wildberger1 , SCAM Bekkers1 , 1Maastricht University Medical Centre (MUMC) - Maastricht - Netherlands (The) , 2Department of Clinical Epidemiology & Medical Technology Assessment - Maastricht - Netherlands (The) , 3Duke University Medical Center, Duke Cardiovascular Magnetic Resonance Centre - Durham - United States of America ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii228

Background 
A cardiac magnetic resonance imaging (CMR) directed strategy improves the diagnostic yield of invasive coronary angiography (ICA) in stable coronary artery disease (CAD). Evidence on the diagnostic accuracy of CMR to detect obstructive CAD in non-ST elevation myocardial infarction (NSTEMI) is limited as is its role to identify myocardial infarction with non-obstructive coronary arteries (MINOCA) in the current high-sensitivity cardiac troponin (hs-cTn) era.

Purpose 
To investigate the diagnostic role of CMR in suspected NSTEMI, especially to detect obstructive CAD.

Methods
This study is a sub-analysis of a randomized controlled trial that investigated whether a non-invasive imaging first strategy safely reduced the number of ICA compared to routine clinical care in suspected NSTEMI (acute chest pain, non-diagnostic electrocardiogram, hs-cTnT levels >14 ng/L). All patients underwent CMR prior to ICA (1 day, range 0-6 days). A stepwise approach was used to assess the diagnostic accuracy of CMR to detect obstructive CAD (stenosis =70%). Regional abnormalities in =2 adjacent segments on cine, T2-weighted and delayed enhancement imaging suggestive of underlying CAD were evaluated first and when normal or non-diagnostic, on adenosine-stress perfusion imaging as a second step (Figure).

Results 
Of 51 patients included (63±10 years, 51% male), 34 (67%) had obstructive and 17 (33%) had non-obstructive CAD. The sensitivity, specificity and overall accuracy of step one and two were 71%, 71% and 71% vs. 80%, 92% and 86%, respectively. When both steps were combined, the sensitivity, specificity and overall accuracy were 94%, 65% and 84%, respectively. In the 17 patients with non-obstructive CAD, CMR still showed an MI in 5 (29%) and stress cardiomyopathy in one. When CMR was normal or non-diagnostic, MINOCA was diagnosed on clinical judgement in 4 additional and remained unknown in 7 patients.

Conclusion
CMR, particularly stress perfusion imaging, accurately detects obstructive CAD in hs-cTnT-positive suspected NSTEMI. Non-obstructive CAD is common with almost one-third having MINOCA by CMR.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are